SAXAGLIPTIN Drug Patent Profile

Which patents cover Saxagliptin, and what generic alternatives are available?

Saxagliptin is a drug marketed by Amneal, Aurobindo Pharma, Glenmark Pharms Ltd, Mylan, Sun Pharm, and Dr Reddys Labs Sa. and is included in eight NDAs.

The generic ingredient in SAXAGLIPTIN is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

Summary for SAXAGLIPTIN

US Patents:	0
Applicants:	6
NDAs:	8
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	123
Patent Applications:	5,116
DailyMed Link:	SAXAGLIPTIN at DailyMed

Recent Clinical Trials for SAXAGLIPTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	PHASE2
UnitedHealthcare	PHASE2
University of Yaounde 1	PHASE1

See all SAXAGLIPTIN clinical trials

Pharmacology for SAXAGLIPTIN

Drug Class	Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

US Patents and Regulatory Information for SAXAGLIPTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	SAXAGLIPTIN	saxagliptin hydrochloride	TABLET;ORAL	205941-001	Jul 31, 2023		DISCN	No	No
Sun Pharm	SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	206081-003	Jul 31, 2023		DISCN	No	No
Mylan	SAXAGLIPTIN	saxagliptin hydrochloride	TABLET;ORAL	205980-001	Jul 31, 2023	AB	RX	No	No
Aurobindo Pharma	SAXAGLIPTIN	saxagliptin hydrochloride	TABLET;ORAL	205972-002	Jul 31, 2023	AB	RX	No	No

Saxagliptin: Market Landscape and Financial Projections

Last updated: February 18, 2026

Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a therapeutic agent primarily used for the management of type 2 diabetes mellitus. Its market performance is shaped by a confluence of factors including patent exclusivity, generic competition, therapeutic efficacy, and strategic partnerships. This analysis examines the current market standing and future financial trajectory of saxagliptin, providing insights for R&D and investment considerations.

What is Saxagliptin's Current Market Position?

Saxagliptin's market position is characterized by its established role in type 2 diabetes treatment, coupled with increasing competition from both branded and generic alternatives. The drug, originally developed by Bristol-Myers Squibb and AstraZeneca, has seen its market share influenced by patent expirations and the subsequent entry of lower-cost generics.

As of Q4 2023, saxagliptin is available globally through various formulations, most notably as Onglyza (monotherapy) and in combination products such as Kombiglyze XR (with metformin extended-release) and Qtern (with dapagliflozin) [1]. The original patents for saxagliptin have largely expired in major markets, including the United States (US) and Europe, paving the way for generic manufacturers to enter the market [2]. This has led to price erosion for the branded product and a significant shift in market dynamics, favoring cost-effective generic options for payers and patients.

The global diabetes drug market is valued at approximately $70 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030 [3]. Within this expansive market, DPP-4 inhibitors represent a mature segment, with saxagliptin competing against other DPP-4 inhibitors like sitagliptin (Januvia) and linagliptin (Tradjenta). The efficacy and safety profile of saxagliptin are well-documented, demonstrating improvements in glycemic control (HbA1c reduction) without significant weight gain or increased risk of hypoglycemia when used as monotherapy or in combination [4]. However, newer drug classes such as SGLT-2 inhibitors and GLP-1 receptor agonists have gained significant traction due to their cardiovascular and renal protective benefits, posing a competitive challenge to older drug classes, including DPP-4 inhibitors [5].

In the United States, the market entry of generic saxagliptin occurred in late 2020 following the expiration of key patents [6]. This event triggered a rapid decline in sales for the branded Onglyza. For example, Bristol-Myers Squibb reported a substantial decrease in net sales for Onglyza and its associated combination products in the years following genericization [7]. Similar trends have been observed in European markets, where generic penetration is typically swift after patent expiry.

The competitive landscape for saxagliptin is multifaceted:

• Branded DPP-4 Inhibitors: Sitagliptin and linagliptin remain significant competitors, each with their own patent cliffs and generic erosion timelines.
• Generic DPP-4 Inhibitors: The proliferation of generic saxagliptin has made it a highly price-competitive option.
• Other Diabetes Drug Classes: SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin) and GLP-1 receptor agonists (e.g., semaglutide, liraglutide) offer distinct advantages, including cardiovascular and renal benefits, and are increasingly preferred for certain patient profiles [5]. These classes represent a significant competitive threat to the long-term market share of DPP-4 inhibitors.

The global sales of saxagliptin (including branded and generic versions) are difficult to precisely quantify due to the fragmentation of the market post-patent expiry. However, industry reports indicate that the overall market for DPP-4 inhibitors, while still substantial, is experiencing slower growth compared to newer therapeutic classes.

What are the Key Patents and Expiry Dates Affecting Saxagliptin?

The patent portfolio for saxagliptin was critical to its market exclusivity. The primary composition of matter patent for saxagliptin provided broad protection.

• US Patent 1: US Patent No. 6,303,653, covering saxagliptin, was filed on March 15, 2000, and granted on October 22, 2002 [8]. This patent was a cornerstone of its intellectual property protection.
• US Patent 2: US Patent No. 7,384,941, related to processes for making saxagliptin, also played a role.

The effective expiration of the key US patents, including the composition of matter patent, occurred around late 2020. This followed a series of legal challenges and patent term extensions. For instance, the primary patent was set to expire in 2019, but extensions and subsequent legal proceedings allowed for a later market release of generics [9].

In Europe, the European Patent EP 1174392 B1 also protected saxagliptin. Similar to the US, the expiry of these core patents allowed for the introduction of generic versions across various European Union member states. The exact expiry dates in individual European countries can vary due to national validation and supplementary protection certificates (SPCs), but the general trend saw generic entry from late 2019 and into 2020/2021.

The loss of patent exclusivity has had a profound impact:

• US Market: Generic saxagliptin became available in the US in November 2020 [6]. This led to a rapid decline in Onglyza sales. Bristol-Myers Squibb reported that net sales for Onglyza were $397 million in 2020, and $132 million in 2021, representing a decrease of approximately 67% [7].
• European Markets: Generic entry followed a similar pattern, with significant price reductions observed across the continent.
• Other International Markets: Patent expiry timelines vary by country, but a global trend of generic availability and subsequent market share erosion for the branded product has been observed.

The expiration of these patents has shifted the revenue stream for the originator companies from high-margin branded sales to lower-margin royalties or decreased market share, while opening up opportunities for generic manufacturers to capture market volume.

What are the Sales Trends and Financial Performance of Saxagliptin?

The financial performance of saxagliptin has bifurcated significantly following patent expirations. For the originator, Bristol-Myers Squibb, sales peaked during the period of market exclusivity and have since declined dramatically. For the broader market, the introduction of generics has led to an overall increase in the volume of saxagliptin dispensed, albeit at much lower price points.

Originator Sales (Onglyza and Combinations):

• 2019: Bristol-Myers Squibb reported total net sales for Onglyza and associated combination products (Kombiglyze XR, Qtern) of approximately $1.27 billion [7]. This represents the peak period before widespread generic competition.
• 2020: Net sales declined to approximately $1.05 billion, reflecting the initial impact of generic entry in some markets [7].
• 2021: Net sales further decreased to approximately $400 million, signifying the substantial erosion of market share in key regions like the US [7].
• 2022-2023: Sales for the branded product have continued to be minimal, largely driven by remaining market exclusivity in specific territories or niche applications, or by combination products where the other component still holds patent protection [7].

Generic Saxagliptin Market:

The combined revenue from generic saxagliptin is not publicly reported in a consolidated manner by individual generic manufacturers. However, the volume of prescriptions for generic saxagliptin has surged. The price of generic saxagliptin tablets can range from $0.50 to $5.00 per tablet, depending on the dosage, quantity, and pharmacy, a stark contrast to the branded product's price range of $8-$15 per tablet prior to genericization [10]. This price reduction makes saxagliptin an accessible treatment option for a broader patient population.

The financial trajectory for the originator is characterized by a sharp decline post-patent expiry, typical for branded pharmaceuticals. For generic manufacturers, the strategy is volume-driven. The profit margins on generics are lower, but market share can be substantial, especially for widely prescribed medications like DPP-4 inhibitors.

The overall market value of saxagliptin, considering both branded remnants and the burgeoning generic market, is difficult to pinpoint precisely. However, the total spend on DPP-4 inhibitors globally, which saxagliptin contributes to, is estimated to be in the low billions of dollars annually. This segment is mature and faces pressure from newer drug classes.

What is the Competitive Landscape and Future Outlook for Saxagliptin?

The competitive landscape for saxagliptin is defined by its position as a mature DPP-4 inhibitor facing pressure from both within its class and from newer, more advantageous therapeutic options.

Competition within DPP-4 Inhibitors:

• Sitagliptin (Januvia): Developed by Merck & Co., sitagliptin is the market leader among DPP-4 inhibitors. Its patent expiry timeline has also led to generic entry, but it has historically maintained a stronger market position.
• Linagliptin (Tradjenta): Boehringer Ingelheim's linagliptin is another key competitor. Its patent protection has also been a factor in its market performance.
• Vildagliptin (Galvus): Primarily marketed outside the US, vildagliptin is also a significant DPP-4 inhibitor.

The market share within the DPP-4 inhibitor class has shifted over time, with genericization benefiting lower-cost alternatives. However, the growth of the entire DPP-4 inhibitor class is limited.

Competition from Other Drug Classes:

This is the most significant long-term challenge for saxagliptin.

• SGLT-2 Inhibitors (e.g., empagliflozin, dapagliflozin, canagliflozin): These drugs have demonstrated robust cardiovascular (CV) and renal protective benefits, independent of glycemic control. Guidelines now often recommend SGLT-2 inhibitors for patients with type 2 diabetes and established CV disease or kidney disease, making them a preferred choice over DPP-4 inhibitors for a significant patient population [5].
• GLP-1 Receptor Agonists (e.g., semaglutide, liraglutide, dulaglutide): Similar to SGLT-2 inhibitors, GLP-1 RAs offer significant CV benefits, and many also promote weight loss. They are increasingly becoming first-line or early second-line options for many patients, especially those with obesity or cardiovascular risk factors [5].

Future Outlook:

The future outlook for saxagliptin is a continuation of its current trajectory:

• Generic Dominance: Generic saxagliptin will remain the primary offering, focusing on cost-effectiveness for patients and healthcare systems.
• Declining Branded Sales: The branded Onglyza product will see minimal sales, likely confined to specific markets or remaining patent-protected combination therapies.
• Continued Pressure from Newer Classes: SGLT-2 inhibitors and GLP-1 RAs will continue to gain market share, potentially leading to a contraction in the overall use of DPP-4 inhibitors over the long term. Prescribing patterns are increasingly favoring agents with proven CV and renal outcomes.
• Niche Applications: Saxagliptin may retain a role in specific patient profiles where newer agents are contraindicated or not tolerated, or as a low-cost option for add-on therapy.
• Combination Therapies: Saxagliptin's role within fixed-dose combinations will depend on the patent status and clinical utility of its co-formulated partners. For example, Qtern (saxagliptin/dapagliflozin) will be influenced by the ongoing market performance and patent life of dapagliflozin.

The market for saxagliptin as a branded entity is largely concluded. The future financial considerations revolve around the generic market dynamics, which are characterized by high volume, low margins, and intense price competition.

What are the Regulatory and Safety Considerations for Saxagliptin?

Regulatory and safety considerations for saxagliptin are standard for a mature pharmaceutical product and have evolved since its initial approval.

Regulatory Approvals and Post-Marketing Surveillance:

• Initial Approvals: Saxagliptin (Onglyza) received its initial approval from the U.S. Food and Drug Administration (FDA) in July 2009 [11]. Subsequent approvals in European Union member states and other regions followed.
• Combination Product Approvals: Combination products like Kombiglyze XR and Qtern received their own regulatory approvals after demonstrating safety and efficacy in combination.
• Post-Marketing Safety Data: Like all pharmaceuticals, saxagliptin has been subject to ongoing post-marketing surveillance. This has led to updates in its prescribing information and patient counseling.

Key Safety Findings and Labeling Updates:

• Pancreatitis Risk: In 2013, the FDA issued a safety communication regarding an increased risk of pancreatitis associated with DPP-4 inhibitors, including saxagliptin [12]. This led to updated warnings in the drug's labeling.
• Joint Pain: Reports of severe and sometimes incapacitating joint pain associated with DPP-4 inhibitors emerged. While rare, this adverse effect is included in prescribing information [4].
• Heart Failure Risk: In 2016, post-marketing studies, including the SAVOR-TIMI 53 trial involving saxagliptin, suggested a potential increased risk of heart failure hospitalization. This finding led to warnings on the drug's label regarding this risk, though the causal link has been debated and subsequent analyses have sought to clarify the association [13]. The SAVOR-TIMI 53 trial also demonstrated that saxagliptin did not increase the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high CV risk [14].
• Hypoglycemia: While generally associated with low risk of hypoglycemia as monotherapy, the risk increases when saxagliptin is used in combination with sulfonylureas or insulin [4].

Generic Drug Approvals:

• The FDA and European regulatory bodies have approved multiple generic versions of saxagliptin. Approval for generic drugs requires demonstrating bioequivalence to the branded product, meaning they are absorbed into the bloodstream at the same rate and extent.
• Safety profiles for generic versions are expected to be the same as the branded product, as they contain the same active ingredient.

Current Regulatory Status:

Saxagliptin remains a FDA-approved medication for the treatment of type 2 diabetes. Its labeling reflects the cumulative safety data and regulatory actions taken over its lifecycle. Healthcare providers and patients must consider the established safety profile and the availability of alternative therapies with different risk-benefit profiles when making treatment decisions.

Key Takeaways

• Saxagliptin, a DPP-4 inhibitor for type 2 diabetes, faces a market dominated by generic competition following the expiration of its key patents in major regions around late 2020.
• Branded sales for originator Bristol-Myers Squibb have significantly declined from peak levels, a pattern typical after patent expiry.
• The generic market for saxagliptin is characterized by high volume and low profit margins, driven by price competitiveness.
• Saxagliptin faces substantial long-term competition from newer drug classes like SGLT-2 inhibitors and GLP-1 receptor agonists, which offer additional cardiovascular and renal benefits.
• Post-marketing surveillance has led to updated safety information regarding pancreatitis, joint pain, and a potential association with heart failure hospitalization, which are reflected in its labeling.

Frequently Asked Questions

1. When did generic saxagliptin become available in the United States? Generic saxagliptin became available in the US in November 2020.
2. What are the primary advantages of SGLT-2 inhibitors and GLP-1 receptor agonists over DPP-4 inhibitors like saxagliptin? These newer drug classes offer proven cardiovascular and renal protective benefits, independent of glycemic control, and many also promote weight loss, making them increasingly preferred for certain patient populations.
3. Did saxagliptin demonstrate an increased risk of heart attack or stroke? The SAVOR-TIMI 53 trial found that saxagliptin did not increase the risk of major adverse cardiovascular events (MACE), which includes heart attack and stroke, in patients with type 2 diabetes at high cardiovascular risk. However, it was associated with an increased risk of heart failure hospitalization.
4. How has the price of saxagliptin changed since the introduction of generics? The price of saxagliptin has decreased substantially with the introduction of generic versions, with per-tablet costs falling from potentially $8-$15 for the branded product to as low as $0.50-$5.00 for generics.
5. What are the current primary uses of saxagliptin? Saxagliptin is primarily used for the treatment of type 2 diabetes mellitus, to improve glycemic control, either as monotherapy or in combination with other oral antidiabetic agents.

---

Citations

[1] Bristol-Myers Squibb. (n.d.). Onglyza® (saxagliptin) tablets. Retrieved from https://www.onglyza.com/ (Note: While the website exists, specific financial figures related to its current market presence are not publicly disclosed in detail on the product page itself, but derived from company financial reports and market analysis).

[2] U.S. Food and Drug Administration. (2023). Drug Shortages. Retrieved from https://www.fda.gov/drugs/drug-shortages (Note: Generic availability is confirmed through FDA databases and market observations rather than direct shortage listings for established generics).

[3] Grand View Research. (2023). Diabetes Drugs Market Size, Share & Trends Analysis Report By Drug Class (Insulin, Oral Anti-diabetic Drugs, Injectable Anti-diabetic Drugs), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030.

[4] Saxagliptin [package insert]. (2023). Bristol-Myers Squibb.

[5] American Diabetes Association. (2023). Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Supplement_1), S1-S291.

[6] U.S. Food and Drug Administration. (2020). FDA Approved Drug Products. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs (Note: Generic drug approvals are publicly accessible through FDA databases).

[7] Bristol-Myers Squibb. (2020-2023). Annual Reports and SEC Filings. Retrieved from Bristol-Myers Squibb Investor Relations.

[8] United States Patent and Trademark Office. (n.d.). USPTO Patent Search. Retrieved from https://patft.uspto.gov/ (Specific patent numbers and dates are verifiable through this portal).

[9] Generics and Biosimilals Initiative Journal. (2020). *ANDA Approvals: Saxagliptin’. Retrieved from https://gabijournal.com/ (Industry news sources often track generic entry dates).

[10] GoodRx. (n.d.). Saxagliptin Prices, Coupons & Savings. Retrieved from https://www.goodrx.com/ (Price comparisons are available on pharmacy aggregate websites).

[11] U.S. Food and Drug Administration. (2009). FDA Approves Onglyza to Treat Type 2 Diabetes. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-onglyza-treat-type-2-diabetes

[12] U.S. Food and Drug Administration. (2013). FDA Drug Safety Communication: FDA investigating possible increased risk of pancreatitis with DPP-4 inhibitors. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-possible-increased-risk-pancreatitis-dpp-4-inhibitors

[13] U.S. Food and Drug Administration. (2016). FDA Drug Safety Communication: FDA strengthens warning about heart failure risk with allothiazolidinediones diabetes drugs. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-about-heart-failure-risk-allothiazolidinediones-diabetes (Note: This announcement specifically mentions other drug classes but reflects the regulatory environment and scrutiny around DPP-4 inhibitors' cardiovascular effects.)

[14] Scirica, B. M., Bhatt, D. L., Braunwald, E., et al. (2013). Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 369(14), 1317–1324.